Annual report pursuant to Section 13 and 15(d)

Transactions with BioXcel (Details)

v3.19.1
Transactions with BioXcel (Details)
$ in Thousands
12 Months Ended
Apr. 05, 2018
USD ($)
Nov. 07, 2017
USD ($)
shares
Jun. 30, 2017
USD ($)
Dec. 31, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
shares
Transactions with BioXcel          
Common shares, issued | shares       15,663,221 9,907,548
Note Payable — Parent       $ (371) $ 371
BioXcel Corporation          
Transactions with BioXcel          
Note Payable — Parent         $ (371)
BioXcel Corporation | Asset contribution agreement          
Transactions with BioXcel          
Common shares, issued | shares   9,480,000      
Lump sum payment to parent   $ 5,000      
Period specified for payment   60 days      
Cumulative net sales   $ 50,000      
Payment to (received from) related party $ 1,000        
Maximum borrowing capacity   1,000      
BioXcel Corporation | Collaborative services agreement          
Transactions with BioXcel          
Term of agreement     5 years    
BioXcel Corporation | Development milestones          
Transactions with BioXcel          
Potential milestone payments     $ 10,000    
BioXcel Corporation | Sales milestones          
Transactions with BioXcel          
Potential milestone payments     $ 30,000    
Maximum milestone (as as percent)     3    
BioXcel Corporation | Payable upon later 12 months IPO and first dosing for BXCL501 | Asset contribution agreement          
Transactions with BioXcel          
Lump sum payment to parent   $ 500      
Period specified for payment   12 months      
BioXcel Corporation | Payable upon later of 12 months of IPO and specified milestones | Asset contribution agreement          
Transactions with BioXcel          
Lump sum payment to parent   $ 500      
Period specified for payment   12 months